Literature DB >> 12731339

[The role of medical schools in progressive health care].

Imre Boncz1, Andor Sebestyén.   

Abstract

AIM: To analyse the predicted and observed role of medical schools in the progressive health care. DATA AND METHODS: The data derives from the financial database of the National Health Insurance Fund (NHIF) and covering the period 1998-2001. In this study the authors calculated the market share of the medical schools within the financing of the NHIF in the field of out- and in-patient care, renal dialysis, CT/MRI examinations, task financed services under special rules and fee for progressive (tertier level) care. The authors performed a detailed analysis concerning the Diagnosis Related Groups (DRG) of active inpatient care, where the market share of medical schools was calculated within the TOP-15 DRGs with highest and lowest point value, and within the TOP-15 most common and most infrequent DRGs.
RESULTS: The market share of medical schools increased from 13.7% (1998) to 15.0% (2001). The increase was significant in the active and chronic in-patient care and in renal dialysis. The market share of medical schools from progressive fee decreased from 32.3% (1998) to 26.5% (2001). Within the active in-patient care the medical schools provide health care for 37.7% of the most difficult cases with highest DRG value and for 30.1% of the patients with rare diseases. The market share of the medical schools is much lower in cases with lowest DRG value (10.2%) and in most common cases (9.8%).
CONCLUSION: The medical schools fulfilled their expected role in the progressive (tertier) care, answering the public and professional expectations.

Entities:  

Mesh:

Year:  2003        PMID: 12731339

Source DB:  PubMed          Journal:  Orv Hetil        ISSN: 0030-6002            Impact factor:   0.540


  1 in total

1.  Financing of health care services in Hungary.

Authors:  Imre Boncz; Júlia Nagy; Andor Sebestyén; László Korösi
Journal:  Eur J Health Econ       Date:  2004-10
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.